TY - JOUR
T1 - Double‐Blind Crossover Trial of Diltiazem versus Propranolol in the Management of Thyrotoxic Symptoms
AU - Milner, Mark R.
AU - Gelman, Kenneth M.
AU - Phillips, Robert A.
AU - Fuster, Valentin
AU - Davies, Terry F.
AU - Goldman, Martin E.
N1 - Copyright:
Copyright 2016 Elsevier B.V., All rights reserved.
PY - 1990
Y1 - 1990
N2 - We compared the efficacy of diltiazem and propranolol in a randomized, prospective, double‐blind, crossover study in six patients with untreated thyrotoxicosis (mean age 31 yrs). The patients received either diltiazem 60 mg orally four times a day or propranolol 40 mg orally four times a day, each for 1 week, separated by a 3‐day drug‐free period. Blood pressure, heart rate, thyroid hormone levels (free T4, T3), electrocardiogram, two‐dimensional and M‐mode echocardiograms, and Doppler studies were performed. In addition, 8 clinical signs and 18 symptoms of thyrotoxicosis were graded. All subjects felt better with drug therapy, with three preferring diltiazem to propranolol. No significant difference in clinical response or in hemodynamic effects was noted between the agents. These data suggest that diltiazem may serve as an alternative therapy for β blockers in controlling thyrotoxic symptoms in patients in whom β blockade may be contraindicated. 1990 Pharmacotherapy Publications Inc.
AB - We compared the efficacy of diltiazem and propranolol in a randomized, prospective, double‐blind, crossover study in six patients with untreated thyrotoxicosis (mean age 31 yrs). The patients received either diltiazem 60 mg orally four times a day or propranolol 40 mg orally four times a day, each for 1 week, separated by a 3‐day drug‐free period. Blood pressure, heart rate, thyroid hormone levels (free T4, T3), electrocardiogram, two‐dimensional and M‐mode echocardiograms, and Doppler studies were performed. In addition, 8 clinical signs and 18 symptoms of thyrotoxicosis were graded. All subjects felt better with drug therapy, with three preferring diltiazem to propranolol. No significant difference in clinical response or in hemodynamic effects was noted between the agents. These data suggest that diltiazem may serve as an alternative therapy for β blockers in controlling thyrotoxic symptoms in patients in whom β blockade may be contraindicated. 1990 Pharmacotherapy Publications Inc.
UR - http://www.scopus.com/inward/record.url?scp=0025272397&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025272397&partnerID=8YFLogxK
U2 - 10.1002/j.1875-9114.1990.tb02556.x
DO - 10.1002/j.1875-9114.1990.tb02556.x
M3 - Article
C2 - 2349134
AN - SCOPUS:0025272397
SN - 0277-0008
VL - 10
SP - 100
EP - 106
JO - Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
JF - Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
IS - 2
ER -